Amarin Corporation

Last Updated:

Q3 '20


quotes and stock data delayed 15 minutes



Burn Rate (Qtr)


Company Profile

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date


Cardiovascular disease (triglyceride lowering)

Quarterly Sales (Approved)

February 26, 2021 (Est)

Icosapent Etheyl (generic Vascepa)

Cardiovascular Disease / Triglycerides

Generic Icosapent Ethyl (patent lit/sales)

Hikma files response to complaint - Dec 21, 2020 (extendable)



Phase 2


Recent Posts

See what the community is saying - click to see full post

AMRN files new patent lawsuit - Initial thoughts

AMRN - Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China

AMRN - VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronar

AMRN - Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

AMRN - Petition for panel rehearing and en banc review DENIED

AMRN - New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Associatio

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon